Saturday 17 October 2026
Export TARA’s income statement to Excel — free account
Protara Therapeutics, Inc.
TARA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 2.86% and free cash flow fell 28.1%, each against the same quarter a year earlier.
2.33
0.07
−2.92%
Follow TARA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 70.00 | 44.00 | 60.00 | 8.80 | 15.86 | 5.94 | 2.38 | 1.04 | 1.60 | 2.77 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 600.00 | 110.00 | 116.00 | 157.60 | 67.08 | 25.20 | 7.15 | 4.18 | 10.48 | 7.82 | |||||
| People | |||||||||||||||
| People | Employees | 19 | 16 | 17 | 12 | 29 | 32 | 25 | 27 | 33 | 51 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (29) | (30) | (21) | (8) | (34) | (47) | (66) | (40) | (45) | (57) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (29) | (30) | (21) | (8) | (34) | (47) | (66) | (40) | (45) | (57) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 3 | 32 | 0 | 0 | (1) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (68.80) | (85.20) | (46.00) | (3.04) | (4.70) | (4.21) | (5.86) | (3.57) | (2.17) | (1.34) | |||||
| Cash flow | (57.20) | (51.75) | (51.33) | (1.94) | (3.24) | (3.07) | (2.35) | (3.31) | (1.74) | (1.32) | |||||
| Capex | (0.65) | (0.08) | (0.26) | (0.18) | (0.12) | (0.05) | (0.01) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (57.86) | (51.83) | (51.60) | (2.13) | (3.36) | (3.12) | (2.36) | (3.32) | (1.74) | (1.32) | |||||
| Book value | 92.83 | 80.43 | 45.17 | (0.83) | 27.54 | 14.41 | 9.07 | 6.03 | 8.12 | 4.59 | |||||
| Shares, m | 0 | 0 | 0 | 3 | 7 | 11 | 11 | 11 | 21 | 43 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (24) | (22) | (23) | (5) | (23) | (35) | (26) | (38) | (36) | (56) | ||||
| Capex | 0 | 0 | 0 | 0 | (1) | (1) | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (24) | (22) | (23) | (5) | (24) | (35) | (27) | (38) | (36) | (56) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 38 | 34 | 20 | (3) | 167 | 89 | 80 | 63 | 161 | 149 | ||||
| Total debt | — | — | — | — | 1 | 7 | 6 | — | — | — | |||||
| Net debt | (41) | (42) | (22) | (1) | (169) | (91) | (84) | (66) | (170) | (156) | |||||
| Shareholders’ equity | 38 | 35 | 20 | (2) | 199 | 162 | 102 | 68 | 167 | 196 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (51.37) | (83.91) | (61.42) | (63.29) | (33.25) | (25.15) | (46.14) | (42.05) | (34.25) | (29.39) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (70.36) | (41.99) | (236.63) | (994.46) | 0.00 | (98.74) | |||||
| ROE | (56.02) | (142.13) | (341.61) | 488.15 | (34.48) | (26.17) | (49.96) | (47.44) | (37.88) | (31.60) | |||||
Negative figures in brackets.
Fiscal years to Dec 2014 · latest quarter Sep 2014
Charts ten years each
Protara Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MENS Jyong Biotech Ltd. | $147.0M | — | — | — | — | — | — | — | Compare |
| MSLE Satellos Bioscience Inc. | $145.1M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $143.5M | — (loss-making) | — (loss-making) | −98.86% (below 0%: shrinking) | n/m | +23.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TARA Protara Therapeutics, Inc. | $141.8M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | |
| ALXO ALX Oncology Holdings Inc. | $138.3M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | +31.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NKTX Nkarta, Inc. | $138.2M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AVXL Anavex Life Sciences Corp. | $137.2M | — (loss-making) | — | — | n/m | +27.02% (above 0%: growing) | — | 0.00% | Compare |
| KRRO Korro Bio, Inc. | $137.1M | — (loss-making) | — (loss-making) | −86.28% (below 0%: shrinking) | n/m | +12.07% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ANTX AN2 Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | +7.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $138.3M | — | — | −98.86% | — | +12.07% | 0.00% | 0.00% |
Protara Therapeutics, Inc. (TARA) key facts
- Protara Therapeutics, Inc. (TARA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TARA traded at $2.33, a market capitalization of $141.8 million.
- Return on equity was −31.6% and debt-to-equity 0.00.
Protara Therapeutics, Inc. (TARA) Latest News
No news at this impact. Lower the threshold for more.